---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023607"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:51:50.578424+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Q2 net loss $1.3M; cash $4.3M; share exchange with FITTERS on track

## Summary
- Net loss of $1.3M (incl. $7K stock comp) vs $3.3M in Q2 2024; revenue not reported.
- Cash and equivalents $4.3M at June 30, 2025, estimated to fund into Q4 2025.
- R&D expenses dropped to $0.1M from $2.0M after UK subsidiary liquidation in Jan 2025.
- Agreed share exchange: FITTERS will exchange 100% of FITTERS Sdn. Bhd. for ~19.99% of CYCC common stock; $1M cash added; special meeting Sep 4, 2025.
- In July, one-for-15 reverse stock split to meet Nasdaq bid price; $3M Series F convertible preferred raised in June.

## SEC filing metadata
- accession: 0001641172-25-023607
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000164117225023607/0001641172-25-023607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000164117225023607/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023607
- JSON: https://secwatch.observer/filing/0001641172-25-023607.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.